Journal article icon

Journal article

Disability as an outcome in MS clinical trials.

Abstract:

BACKGROUND: Inferences about long-term effects of therapies in multiple sclerosis (MS) have been based on surrogate markers studied in short-term trials. Preventing progressive disability is the key therapeutic goal but there remains no validated definition for its measurement in a trial context. Meanwhile, MS trials continue to shorten and to depend on unvalidated surrogates. Since there have been no treatment claims for improving unremitting disability, worsening of disability in the place...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Neuroscience, WTC Human Genetics
Role:
Author
Journal:
Neurology
Volume:
71
Issue:
9
Pages:
624-631
Publication date:
2008-08-05
DOI:
EISSN:
1526-632X
ISSN:
0028-3878
URN:
uuid:b0b45e4b-aa35-4766-82d9-bc53dfffc52e
Source identifiers:
34233
Local pid:
pubs:34233

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP